170 related articles for article (PubMed ID: 36550137)
1. Safeguarding genome integrity during gene-editing therapy in a mouse model of age-related macular degeneration.
Yin J; Fang K; Gao Y; Ou L; Yuan S; Xin C; Wu W; Wu WW; Hong J; Yang H; Hu J
Nat Commun; 2022 Dec; 13(1):7867. PubMed ID: 36550137
[TBL] [Abstract][Full Text] [Related]
2. Cas9 exo-endonuclease eliminates chromosomal translocations during genome editing.
Yin J; Lu R; Xin C; Wang Y; Ling X; Li D; Zhang W; Liu M; Xie W; Kong L; Si W; Wei P; Xiao B; Lee HY; Liu T; Hu J
Nat Commun; 2022 Mar; 13(1):1204. PubMed ID: 35260581
[TBL] [Abstract][Full Text] [Related]
3. Nme
Hu S; Chen Y; Xie D; Xu K; Fu Y; Chi W; Liu H; Huang J
Clin Transl Med; 2023 Aug; 13(8):e1383. PubMed ID: 37598400
[TBL] [Abstract][Full Text] [Related]
4. Genome surgery using Cas9 ribonucleoproteins for the treatment of age-related macular degeneration.
Kim K; Park SW; Kim JH; Lee SH; Kim D; Koo T; Kim KE; Kim JH; Kim JS
Genome Res; 2017 Mar; 27(3):419-426. PubMed ID: 28209587
[TBL] [Abstract][Full Text] [Related]
5. Lentiviral delivery of co-packaged Cas9 mRNA and a Vegfa-targeting guide RNA prevents wet age-related macular degeneration in mice.
Ling S; Yang S; Hu X; Yin D; Dai Y; Qian X; Wang D; Pan X; Hong J; Sun X; Yang H; Paludan SR; Cai Y
Nat Biomed Eng; 2021 Feb; 5(2):144-156. PubMed ID: 33398131
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive assessment of miniature CRISPR-Cas12f nucleases for gene disruption.
Xin C; Yin J; Yuan S; Ou L; Liu M; Zhang W; Hu J
Nat Commun; 2022 Sep; 13(1):5623. PubMed ID: 36153319
[TBL] [Abstract][Full Text] [Related]
7. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
Soriano V
AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
[TBL] [Abstract][Full Text] [Related]
8. Factors Impacting Efficacy of AAV-Mediated CRISPR-Based Genome Editing for Treatment of Choroidal Neovascularization.
Chung SH; Mollhoff IN; Nguyen U; Nguyen A; Stucka N; Tieu E; Manna S; Meleppat RK; Zhang P; Nguyen EL; Fong J; Zawadzki R; Yiu G
Mol Ther Methods Clin Dev; 2020 Jun; 17():409-417. PubMed ID: 32128346
[TBL] [Abstract][Full Text] [Related]
9. Global detection of DNA repair outcomes induced by CRISPR-Cas9.
Liu M; Zhang W; Xin C; Yin J; Shang Y; Ai C; Li J; Meng FL; Hu J
Nucleic Acids Res; 2021 Sep; 49(15):8732-8742. PubMed ID: 34365511
[TBL] [Abstract][Full Text] [Related]
10. Whole genomic analysis reveals atypical non-homologous off-target large structural variants induced by CRISPR-Cas9-mediated genome editing.
Tsai HH; Kao HJ; Kuo MW; Lin CH; Chang CM; Chen YY; Chen HH; Kwok PY; Yu AL; Yu J
Nat Commun; 2023 Aug; 14(1):5183. PubMed ID: 37626063
[TBL] [Abstract][Full Text] [Related]
11. CRISPR/Cas9-induced structural variations expand in T lymphocytes in vivo.
Wu J; Zou Z; Liu Y; Liu X; Zhangding Z; Xu M; Hu J
Nucleic Acids Res; 2022 Oct; 50(19):11128-11137. PubMed ID: 36243978
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic Genome Editing and In Vivo Delivery.
Ramirez-Phillips AC; Liu D
AAPS J; 2021 Jun; 23(4):80. PubMed ID: 34080099
[TBL] [Abstract][Full Text] [Related]
13. Gene editing prospects for treating inherited retinal diseases.
Benati D; Patrizi C; Recchia A
J Med Genet; 2020 Jul; 57(7):437-444. PubMed ID: 31857428
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and long-term safety of CRISPR/Cas9 genome editing in the SOD1-linked mouse models of ALS.
Deng HX; Zhai H; Shi Y; Liu G; Lowry J; Liu B; Ryan ÉB; Yan J; Yang Y; Zhang N; Yang Z; Liu E; Ma YC; Siddique T
Commun Biol; 2021 Mar; 4(1):396. PubMed ID: 33767386
[TBL] [Abstract][Full Text] [Related]
15. CRISPR-based VEGF suppression using paired guide RNAs for treatment of choroidal neovascularization.
Chung SH; Sin TN; Dang B; Ngo T; Lo T; Lent-Schochet D; Meleppat RK; Zawadzki RJ; Yiu G
Mol Ther Nucleic Acids; 2022 Jun; 28():613-622. PubMed ID: 35614998
[TBL] [Abstract][Full Text] [Related]
16. CRISPR/Cas9-A Promising Therapeutic Tool to Cure Blindness: Current Scenario and Future Prospects.
Ahmad I
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232782
[TBL] [Abstract][Full Text] [Related]
17. Development of a CRISPR/Cas9 genome editing toolbox for Corynebacterium glutamicum.
Liu J; Wang Y; Lu Y; Zheng P; Sun J; Ma Y
Microb Cell Fact; 2017 Nov; 16(1):205. PubMed ID: 29145843
[TBL] [Abstract][Full Text] [Related]
18. Compact Cje3Cas9 for Efficient
Chen S; Liu Z; Xie W; Yu H; Lai L; Li Z
CRISPR J; 2022 Jun; 5(3):472-486. PubMed ID: 35686977
[TBL] [Abstract][Full Text] [Related]
19. CRISPR-Cas9 for cancer therapy: Opportunities and challenges.
Chen M; Mao A; Xu M; Weng Q; Mao J; Ji J
Cancer Lett; 2019 Apr; 447():48-55. PubMed ID: 30684591
[TBL] [Abstract][Full Text] [Related]
20. Pre-clinical non-viral vectors exploited for
Rouatbi N; McGlynn T; Al-Jamal KT
Biomater Sci; 2022 Jun; 10(13):3410-3432. PubMed ID: 35604372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
